bobbybobby
FeatureMarketsStocksJoin Us

Thermo Fisher Scientific Inc.

TMO

$472.63

-0.23%

Thermo Fisher Scientific Inc. is a global leader in the healthcare sector, specifically within the medical diagnostics and research industry, providing essential scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents. The company is a dominant, integrated platform player, serving customers across the analytical technologies, specialty diagnostics, life sciences, and lab products and services segments, which gives it a unique competitive moat through its scale and breadth of offerings. The current investor narrative revolves around the company's ability to demonstrate operational resilience and deliver steady growth in a post-pandemic normalization phase, as highlighted by its recent strong quarterly results and raised long-term guidance, while simultaneously navigating new macroeconomic pressures such as inflation and geopolitical tensions.…

Should I buy TMO
Bobby Quantitative Model
Jun 16, 2026

TMO

Thermo Fisher Scientific Inc.

$472.63

-0.23%
Jun 16, 2026
Bobby Quantitative Model
Thermo Fisher Scientific Inc. is a global leader in the healthcare sector, specifically within the medical diagnostics and research industry, providing essential scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents. The company is a dominant, integrated platform player, serving customers across the analytical technologies, specialty diagnostics, life sciences, and lab products and services segments, which gives it a unique competitive moat through its scale and breadth of offerings. The current investor narrative revolves around the company's ability to demonstrate operational resilience and deliver steady growth in a post-pandemic normalization phase, as highlighted by its recent strong quarterly results and raised long-term guidance, while simultaneously navigating new macroeconomic pressures such as inflation and geopolitical tensions.
Should I buy TMO

Related headlines

Bullish
Thermo Fisher Beats Earnings, Raises Outlook Despite Macro Risks

People also watch

Danaher Corporation

Danaher Corporation

DHR

Analysis
IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXX

Analysis
Agilent Technologies

Agilent Technologies

A

Analysis
Waters Corporation

Waters Corporation

WAT

Analysis
Natera

Natera

NTRA

Analysis

TMO 12-Month Price Forecast

Historical Price
Current Price $472.63
Average Target $472.63
High Target $543.5245
Low Target $401.7355

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $614.42 and implied upside of +30.0% versus the current price.

Average Target

$614.42

15 analysts

Implied Upside

+30.0%

vs. current price

Analyst Count

15

covering this stock

Price Range

$378 - $614

Analyst target range

Buy
4 (27%)
Hold
7 (47%)
Sell
4 (27%)

Analyst coverage for TMO is robust, with 7 analysts providing estimates, and the institutional sentiment is overwhelmingly bullish, as evidenced by recent actions from firms like Citigroup and Keybanc upgrading to 'Buy' and 'Overweight' in December 2025. The consensus recommendation, inferred from the institutional ratings, is a 'Buy' or 'Overweight', with an average revenue estimate of $58.18 billion and an average EPS estimate of $37.78 for the forward period, though a specific consensus price target is not provided in the data. The target price range can be inferred from the estimated EPS range of $36.89 (low) to $38.22 (high); applying the forward PE of 17.22x suggests an implied price target range of approximately $635 to $658, which would represent a substantial 35% to 40% upside from the current price of $469.34, signaling strong analyst conviction in a recovery. The wide implied target range, based on EPS estimates, reflects differing assumptions about the company's ability to navigate inflationary pressures and return to its historical growth trajectory, with the high end likely pricing in successful execution of raised long-term guidance and margin expansion, while the low end may factor in prolonged macroeconomic headwinds.

Drowning in data?

Find the real signal!

Chat Now

Drowning in data?

Find the real signal!

Chat Now

TMO Technical Analysis

The stock is in a pronounced downtrend, having declined 17.99% over the past six months and 20.79% year-to-date as of the current date. Trading at a price of $469.34, the stock sits approximately 27% above its 52-week low of $385.46 but 27% below its 52-week high of $643.99, indicating it is in the lower-middle portion of its annual range, which suggests the downtrend has created a potential value zone but with significant technical damage. Recent short-term momentum shows a modest 5.23% gain over the past month, which conflicts with the longer-term negative trends and could signal a tentative stabilization or oversold bounce; however, this is juxtaposed against a stark underperformance relative to the market, evidenced by a 1-month relative strength of +5.31% versus the S&P 500's -0.08% but a deeply negative 1-year relative strength of -9.86%. Key technical levels are clearly defined, with major support at the 52-week low of $385.46 and immediate resistance at the recent recovery high near $527.22 from mid-April; a sustained break below support would signal a continuation of the bearish trend, while a move above the $520-$530 zone could indicate a more durable recovery is underway. The stock's beta of 0.87 indicates it has been less volatile than the broader market during this decline, which is atypical for a downtrend of this magnitude and may suggest the selling pressure has been more systematic than stock-specific.

Beta

0.87

0.87x market volatility

Max Drawdown

-31.4%

Largest decline past year

52-Week Range

$385-$644

Price range past year

Annual Return

+16.7%

Cumulative gain past year

PeriodTMO ReturnS&P 500
1m+7.8%+1.5%
3m+1.7%+13.4%
6m-16.0%+10.9%
1y+16.7%+24.5%
ytd-20.2%+10.0%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now

TMO Fundamental Analysis

Revenue growth remains positive but has moderated from pandemic-era peaks, with the most recent Q4 2025 revenue of $12.22 billion representing a 7.2% year-over-year increase; this growth rate, while solid, reflects a normalization trend as the multi-quarter sequential revenue build from $10.36B in Q1 to $12.22B in Q4 shows consistent execution, though segment data indicates the consumables business ($5.03B) and service segment ($4.97B) are the primary revenue drivers, underscoring the company's resilient recurring revenue model. Profitability is robust, with the company generating a net income of $1.98 billion in Q4 2025 and a trailing net margin of 15.12%; gross margin for the quarter was 37.95%, which is consistent with the trailing gross margin of 37.66%, indicating stable pricing power and cost management despite inflationary pressures cited in recent news. The balance sheet and cash flow position remain strong, with a manageable debt-to-equity ratio of 0.76, a healthy current ratio of 1.89, and substantial free cash flow generation of $6.29 billion on a trailing twelve-month basis; this robust FCF, which supports a FCF yield of approximately 2.9% based on the current market cap, provides ample flexibility for strategic M&A, share repurchases, and dividends, as evidenced by the $3 billion in stock repurchases and $162 million in dividends paid during Q4 2025.

Quarterly Revenue

$12.2B

2025-12

Revenue YoY Growth

+0.07%

YoY Comparison

Gross Margin

+0.37%

Latest Quarter

Free Cash Flow

$6.3B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Consumables
Instruments
Service

Open an Account, get $2 TSLA now!

Open Account Now

Open an Account, get $2 TSLA now!

Open Account Now

Valuation Analysis: Is TMO Overvalued?

Given the company's consistent profitability with a net income of $1.98 billion in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 32.34x, which is significantly higher than the forward PE of 17.22x, indicating the market expects a substantial recovery in earnings over the next twelve months. Compared to sector averages, the trailing PE of 32.34x represents a significant premium; while specific industry average data is not provided in the valuation data, the elevated level suggests the market continues to price in a quality and growth premium for this industry leader, which may be justified by its scale, margins, and resilient cash flows. Historically, the current trailing PE of 32.34x is above the stock's own historical range evident in the data, which has fluctuated between the mid-20s and low-40s over recent years; trading near the higher end of its own historical band, despite the recent price decline, implies that earnings compression has occurred and the market is still pricing in a return to stronger earnings growth, leaving little margin for error if execution falters.

PE

32.3x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 19x~43x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

21.7x

Enterprise Value Multiple

Related headlines

Bullish
Thermo Fisher Beats Earnings, Raises Outlook Despite Macro Risks

People also watch

Danaher Corporation

Danaher Corporation

DHR

Analysis
IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXX

Analysis
Agilent Technologies

Agilent Technologies

A

Analysis
Waters Corporation

Waters Corporation

WAT

Analysis
Natera

Natera

NTRA

Analysis

Product

Partner

Markets

Stocks

© 2026 Flow AI Limited. All Rights Reserved.

Bobby, the world's first financial AI Agent, is developed by Flow AI, an AI-driven company. Flow AI is dedicated to providing global investors with AI-powered financial services across multiple markets.

Waffo.com Limited (authorised distributor): RM 1903, 19/F Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.

Bobby
cs@bobby.ai
Bobby AI
RockFlow Platform
Stock Event
Macro Event
Industry Event
NVDA
AAPL
MSFT
AMZN
GOOG
META
TSLA
Privacy Policy
Terms of Use